Helena Wållberg

1.3k total citations
26 papers, 978 citations indexed

About

Helena Wållberg is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Helena Wållberg has authored 26 papers receiving a total of 978 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Radiology, Nuclear Medicine and Imaging, 13 papers in Oncology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Helena Wållberg's work include Monoclonal and Polyclonal Antibodies Research (20 papers), Radiopharmaceutical Chemistry and Applications (16 papers) and HER2/EGFR in Cancer Research (10 papers). Helena Wållberg is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (20 papers), Radiopharmaceutical Chemistry and Applications (16 papers) and HER2/EGFR in Cancer Research (10 papers). Helena Wållberg collaborates with scholars based in Sweden, Germany and Iran. Helena Wållberg's co-authors include Anna Orlova, Vladimir Tolmachev, Stefan Ståhl, Mattias Sandström, Sharon Stone‐Elander, Anders Wennborg, Sara Ahlgren, Charles Widström, Lars Abrahmsén and Daniel Rosik and has published in prestigious journals such as European Journal of Medicinal Chemistry, Bioconjugate Chemistry and Journal of Nuclear Medicine.

In The Last Decade

Helena Wållberg

26 papers receiving 958 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helena Wållberg Sweden	18	859	462	305	88	60	26	978
Daniel Rosik Sweden	15	931 1.1×	459 1.0×	437 1.4×	90 1.0×	45 0.8×	17	1.1k
Hadis Honarvar Sweden	20	698 0.8×	404 0.9×	309 1.0×	96 1.1×	23 0.4×	30	861
Vania Kenanova United States	15	675 0.8×	271 0.6×	360 1.2×	78 0.9×	40 0.7×	20	862
Anzhelika Vorobyeva Sweden	20	799 0.9×	499 1.1×	330 1.1×	122 1.4×	20 0.3×	73	1.0k
R Boden United Kingdom	17	529 0.6×	200 0.4×	353 1.2×	89 1.0×	43 0.7×	28	801
P A Keep United Kingdom	16	735 0.9×	255 0.6×	483 1.6×	59 0.7×	60 1.0×	22	952
Kedan Lin United States	17	750 0.9×	637 1.4×	431 1.4×	68 0.8×	33 0.6×	25	1.1k
Stephen I. Rudnick United States	9	362 0.4×	270 0.6×	391 1.3×	45 0.5×	23 0.4×	11	798
Christel Larbouret France	18	356 0.4×	652 1.4×	366 1.2×	128 1.5×	41 0.7×	36	971
Erasmus Poku United States	14	419 0.5×	302 0.7×	156 0.5×	97 1.1×	15 0.3×	33	660

Countries citing papers authored by Helena Wållberg

Since Specialization

Citations

This map shows the geographic impact of Helena Wållberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helena Wållberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helena Wållberg more than expected).

Fields of papers citing papers by Helena Wållberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helena Wållberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helena Wållberg. The network helps show where Helena Wållberg may publish in the future.

Co-authorship network of co-authors of Helena Wållberg

This figure shows the co-authorship network connecting the top 25 collaborators of Helena Wållberg. A scholar is included among the top collaborators of Helena Wållberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helena Wållberg. Helena Wållberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheng, Qing, Helena Wållberg, Frank Leigh Lu, et al.. (2016). Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake. EJNMMI Research. 6(1). 58–58. 14 indexed citations

Altai, Mohamed, Helena Wållberg, Hadis Honarvar, et al.. (2014). ¹⁸⁸Re-Z_HER2:V2, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment. Journal of Nuclear Medicine. 55(11). 1842–1848. 23 indexed citations

Altai, Mohamed, Hadis Honarvar, Helena Wållberg, et al.. (2014). Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with 188Re. European Journal of Medicinal Chemistry. 87. 519–528. 19 indexed citations

Wållberg, Helena, Qing Cheng, Frank Leigh Lu, et al.. (2012). HER2-Positive Tumors Imaged Within 1 Hour Using a Site-Specifically ¹¹C-Labeled Sel-Tagged Affibody Molecule. Journal of Nuclear Medicine. 53(9). 1446–1453. 25 indexed citations

Wållberg, Helena, Azita Sohrabian, Karl Andersson, et al.. (2012). Generation and Evaluation of Bispecific Affibody Molecules for Simultaneous Targeting of EGFR and HER2. Bioconjugate Chemistry. 23(9). 1802–1811. 23 indexed citations

Lindberg, Hanna, Camilla Hofström, Mohamed Altai, et al.. (2012). Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus. Tumor Biology. 33(3). 641–651. 20 indexed citations

Altai, Mohamed, Helena Wållberg, Anna Orlova, et al.. (2011). Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules. Amino Acids. 42(5). 1975–1985. 19 indexed citations

Wållberg, Helena, Anna Orlova, Seyed Jalal Hosseinimehr, et al.. (2011). Molecular Design and Optimization of ^99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties. Journal of Nuclear Medicine. 52(3). 461–469. 83 indexed citations

Ahlgren, Sara, Anna Orlova, Helena Wållberg, et al.. (2010). Targeting of HER2-Expressing Tumors Using ¹¹¹In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold. Journal of Nuclear Medicine. 51(7). 1131–1138. 73 indexed citations

10.

Wållberg, Helena, Per‐Åke Löfdahl, Mathias Uhlén, et al.. (2010). Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand. Protein Expression and Purification. 76(1). 127–135. 30 indexed citations

11.

Tolmachev, Vladimir, et al.. (2010). Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. European Journal of Nuclear Medicine and Molecular Imaging. 38(3). 531–539. 46 indexed citations

12.

Jonsson, Andreas, et al.. (2009). Generation of tumour‐necrosis‐factor‐α‐specific affibody¹ molecules capable of blocking receptor binding in vitro. Biotechnology and Applied Biochemistry. 54(2). 93–103. 28 indexed citations

13.

Tran, Thuy, Daniel Rosik, Lars Abrahmsén, et al.. (2009). Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging. 36(11). 1864–1873. 44 indexed citations

14.

Ahlgren, Sara, Helena Wållberg, Thuy Tran, et al.. (2009). Targeting of HER2-Expressing Tumors with a Site-Specifically ^99mTc-Labeled Recombinant Affibody Molecule, Z_HER2:2395, with C-Terminally Engineered Cysteine. Journal of Nuclear Medicine. 50(5). 781–789. 92 indexed citations

15.

Tolmachev, Vladimir, Helena Wållberg, Karl Andersson, et al.. (2009). The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy. European Journal of Nuclear Medicine and Molecular Imaging. 36(9). 1460–1468. 21 indexed citations

16.

Orlova, Anna, Helena Wållberg, Sharon Stone‐Elander, & Vladimir Tolmachev. (2009). On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a ¹²⁴I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model. Journal of Nuclear Medicine. 50(3). 417–425. 120 indexed citations

17.

Wållberg, Helena, Sara Ahlgren, Charles Widström, & Anna Orlova. (2009). Evaluation of the Radiocobalt-Labeled [MMA-DOTA-Cys61]-ZHER2:2395-Cys Affibody Molecule for Targeting of HER2-Expressing Tumors. Molecular Imaging and Biology. 12(1). 54–62. 29 indexed citations

18.

Wållberg, Helena & Anna Orlova. (2008). Slow Internalization of Anti-HER2 Synthetic Affibody Monomer ¹¹¹ In-DOTA-Z _{HER2:342-pep2} : Implications for Development of Labeled Tracers. Cancer Biotherapy and Radiopharmaceuticals. 23(4). 435–442. 120 indexed citations

19.

Wållberg, Helena, A Alveryd, & Kjell Carlsson. (1985). Breast Carcinoma and Benign Breast Lesions. Acta Radiologica Diagnosis. 26(5). 535–541. 5 indexed citations

20.

Wållberg, Helena, A Alveryd, & Kjell Carlsson. (1985). Physical Interpretation of Diaphanograms Using the Computer-Controlled Image Scanner Osiris. Acta Radiologica Diagnosis. 26(4). 417–424. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact